BioPharma Dive

Analysts ‘extremely bullish’ as Telix beams into Novartis’ territory with $1.6B ITM acquisition

Updated: Electra says $350M IPO will help it become a commercial biotech

Xenon pauses phase 3 depression trials after psychosis events

Ozempic-maker turns to Anthropic to turbocharge medical research

Is Moderna, Merck's mRNA cancer vaccine win the start of a 'personalized medicine revolution'?

Takeda’s long-serving R&D chief Andy Plump to retire in wake of pipeline successes

Novartis Lp(a) drug fails to lower cardiovascular risk in closely watched ph. 3 trial

'Fall From Grace'

Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials

Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused

Eli Lilly inks $2.88B Merida buyout for autoimmune drugs against rogue antibodies

Alnylam’s heart drug troubles take center stage at a cardiology conference

The Race to Develop More Medicines Like the New Pancreatic Cancer Drug

Bristol Myers ends deal with Cellares, cell therapy manufacturer to reorg

Vacant lab space, shrinking workforce put Mass. in ‘unique position’ for biotech bounceback

Regenxbio gene therapy refiling plan derailed by FDA hold over spine MRI findings

Amylyx Stock Surges 55% After GLP-1 Blocker Hits All Trial Goals

EyePoint Stock Craters 69% After Drug Trial Failure. It May Be an Overreaction.

AstraZeneca Ends Phase 3 Lung Cancer Drug Trial After Review

Cullinan tees up J&J fight—and $100M payday—as Taiho-partnered drug hits phase 3 cancer goal

Biotech Scores Again With LSD In Anxiety; Stock Rises

Deerfield-backed Boulevard Bio embarks on ‘beautiful path to a cure’ with trio of immunology drugs

Regeneron backs $75M series A for antibody upstart Infinimmune

Why Sionna Therapeutics Stock Is Crashing 91% to a Record Low

FDA approves Replimune melanoma drug previously rejected twice

How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

Pfizer Covid Pill Revenue Plunges 95%. That’s Just One Reason the Stock Is Slipping.

Weight Loss Drug Stocks Slump. What Ozempic Maker Novo Nordisk Said.

GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyard

GSK is implementing a $2.5 billion, three-year restructuring initiative to prioritize late-stage drug development and reorganize its research operations.

MapLight shares sink on mixed ph. 2 schizophrenia readout

7 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug

Capricor Therapeutics shares have plunged after FDA staff raised concerns regarding the efficacy and data of its Duchenne heart disease therapy.

Eli Lilly’s Anticipated Weight Loss Drug Helped People Lose 56 Pounds On Average

5 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

Novo sues Lilly, claiming misleading ads in weight-loss drug battle

Novo Nordisk has filed a lawsuit against Eli Lilly over allegations of false and misleading advertising regarding weight-loss drug efficacy.

An experimental Alzheimer's drug shows some promise as researchers hunt new approaches

Researchers and investors are evaluating new clinical data from Biogen as the firm explores tau-targeting treatments for Alzheimer’s disease.

AstraZeneca and Ionis Stocks Sink on Trial Miss and Analysts See an Overreaction

4 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

Eli Lilly's Market Cap Balloons, Again, On This IPO's Setback

Eli Lilly's market capitalization has risen following a setback for Kailera's oral GLP-1 obesity drug trials in China.

FDA approves Vera Therapeutics kidney disease treatment

The FDA has approved Vera Therapeutics' drug Trutakna to treat primary IgA nephropathy, sparking a new market competition for kidney disease treatments.

Vertex Pharma Makes A $10 Billion Deal; Crinetics Stock Doubles

Vertex Pharmaceuticals is expanding into endocrine disease drugs through a $10 billion acquisition of Crinetics.

FDA’s top gene therapy regulator is leaving his role

Pfizer’s first new ADC from Seagen acquisition fails phase 3 NSCLC trial

AbbVie to Buy Immunology Drugmaker Apogee for $10.9 Billion